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1. Introduction 
Sarcoidosis is a granulomatous disease of unknown cause that can virtually affect any organ 
system. The commonly affected organ areas are thoracic lymph nodes and lungs (90 %). The 
granulomas appears to be due to an aberant immune response to a persistent antigen in a 
susceptible host; the antigen, however, is yet to be identified(Shigemitsu, 2008). The 
diagnosis typically rests on the demonstration of characteristic granulomas in biopsy 
specimens of one or more organs and exclusion of other causes of chronic granulomatous 
inflammation(Boffetta et al., 2009; Pavic et al., 2008b). Sarcoidosis affects more frequently 
young adults. Genetic studies have shown that some major histocompatibility complex 
alleles and tumor necrosis factor (TNF) polymorphisms are associated with an increased risk 
of sarcoidosis. The disease is usually characterized by an increased macrophage and CD4 T-
cell activation, whereas sarcoidosis patients also show suppressed response to antigen 
challenges. The coexistent of hyper- and hypoactivity indicates a state of anergy in the 
immune system(Ji et al., 2009). Relationships betwen granulomatosis and cancers have been 
suspected for a long time(Askling et al., 1999; Brincker and Wilbek, 1974; Pavic and Rousset, 
2008; Romer et al., 1998). Nevertheless, few evidence has been reported until recently. Aside 
from granulomatosis due to infectious disease (eg: opportunist infections), granulomas can 
be observed in cancer patients, mainly in two situations. Patients may rarely present with 
typical sarcoidosis occuring before, during or after the diagnosis of cancer. Secondly 
granulomas may be found as a sarcoid reaction in the vicinity of the tumour itself ore more 
frequently in regional lymph nodes(Pavic et al., 2008a). Sarcoidosis has although been 
reported to occur with some chemotherapeutic agents or immunotherapy such as interferon. 
The presence of granulomas within the tumor tissue or in regional ganglions is a frequent 
situation and corresponds to a defense reaction against the tumor-associated antigen 
(sarcoid like reaction)(Kennedy et al., 2008; Steinfort and Irving, 2009). The precise 
mechanism of the sarcoid-cancer syndrome is not yet clear, though there are several 
descriptions in the literature as to the temporal relationship of granulomas developing in 
cancer and vice versa. The etiology of sarcoidosis and sarcoid reactions in malignancy 
remains uncertain but some speculations have been made(Trikudanathan et al.): 1/ 
induction of robust effector T cell response to a tumor antigen or other products of cancer 
cells either spontaneously or with treatment that result in T helper 1 response along with 
secretion of TH1 cytokines; 2/ increased vulnerability to a potential infective agent due to 
immune system imbalance that occurs with cancer; 3/ radiation therapy and antineoplastic 
agents might enhance granulomatous reactions in tumors; 4/granulomatous reaction could 
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play an important role in the host’s defences against metastatic extension. So granulomatous 
reaction has been associated for some cancers with a better prognosis(O'Connell et al., 1975) 
2. Cancer - sarcoidosis syndrome 
The literature remained very controversial during many years on the association between 
sarcoidosis and cancer(Battesti et al., 1977; Brincker, 1989; Brincker and Wilbek, 1974). The 
association of these two pathologies was first considered as fortuitous(Reich et al., 1995; 
Romer, et al., 1998; Seersholm et al., 1997). The swedish study of Askling et al. published in 
1999 concerns a very large cohort and brings a first objective element of answer to this 
question(Askling, et al., 1999). This study reported on a retrospective cohort's study 
analyzing two registers of patients presenting with sarcoidosis (474 and 8541 patients) 
followed respectively from 1966 till 1980 and from 1964 till 1994. The risk of developping a 
cancer within these patients's group was studied by crossing the results of the cancer's 
registers and of the death's registers. The authors investigated the risk of developping a 
cancer in the sites commonly affected by sarcoidosis. The relative risk of cancer was 
increased equally in both registers of sarcoidosis (RR: 1,3; CI 95 %: 1,2-1,4). The risk of lung 
cancer and non-Hodgkin's lymphoma was doubled in the first decade following the 
diagnosis of sarcoidosis. The relative risk was also increased for the other cancers: 
melanomas (RR: 1,6; CI 95 %: 1-2,3), other skin cancers (RR: 2,8; CI 95 %: 2-3,8) and 
unsignificantly for the hepatocarcinomas (RR: 1,4; CI 95 % 0,8-2,2). Le Jeune et al. studied in 
an English population, the incidence of cancer in patients affected by sarcoidosis ( 1153 
cases) and found a relative risk of 1,65 (CI 95 %: 1,22-2,24)(Le Jeune et al., 2007). Adjusted 
according to the age, the sex and smoking, the risk was significantly increased for the skin 
cancers (RR: 1, 86; CI 95 %: 1,11-3,11) and for the lymphomas (RR: 7,04; CI 95 %: 1,54-32,1). Ji 
et al studied retrospectively 10037 patients having been hospitalized in Germany for a 
sarcoidosis between 1964 and 2004 and found 1045 cases of cancers occuring in this 
patients(Ji, et al., 2009). A 40% overall excess incidence of cancer was noted among 
sarcoidosis patients. Notified cancers were the skin cancers (apart from the melanomas), the 
renal cancers, the extra-thyroid endocrine tumors, the non-Hodgkin's lymphomas and the 
leukemias. The increased incidence was confined mainly to the first year after 
hospitalization. However, for specific cancers, such as squamous cell carcinoma of the skin 
and non-hodgkin’s lymphoma and leukemia, the increases were still significant for patients 
diagnosed later than 1 year after hospitalization, especially for those with multiple 
hospitalizations. A late age at hospitalization was associated with a high risk, which calls for 
clinical attention. All these studies have notified that the association of cancer and 
sarcoidosis was not fortuitous with an increased incidence (about 40 %) of skin cancers, 
lymphomas and probably of renal cancers, cancers of the lungs, endocrine tumors and 
leukemias. Some authors proposed the term of "cancer - sarcoidosis syndrome" to appoint 
this association(Shigemitsu, 2008). The independant course of the two pathologies are 
unconsistent  to consider sarcoidosis as a paraneoplastic syndrome. 
3. Sarcoidosis - lymphoma syndrome 
This term was first used by Brincker to describe the association of systemic sarcoidosis and 
malignant lymphoma(Brincker, 1989). Several cases of lymphomas following various forms 
of systemic sarcoidosis have been published since then. The increased prevalence of 
granulomatous disease during the malignant hemopathies is now well established, 
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especially for Hodgkin's disease (14 %) but also for non hodgkin lymphomas (4 in 7 %) 
(Brincker, 1986a; Brunner et al., 2005). Malignant lymphoproliferative disorders, including B 
cell lymphomas, Hodgkin’s lymphomas, chronic myeloid leukaemias and chronic lymphoid 
leukaelias, are more often seen among patients affected by sarcoidosis, with an incidence 
almost 5,5-fold higher than in general population(Apalla et al., ; Brincker, 1986b). 
Development of lymphoma in an individual with a personal history of sarcoidosis, even 
though rare, is not considered fortuitous. In the vast majority of reported cases, systemic 
sarcoidosis precedes the diagnosis of lymphoma by many years. The sarcoidosis – 
lymphoma syndrome is characterized by a later age of onset of the sarcoidosis (about 41 
years, approximately 10 years more than the age of the classical sarcoidosis). Taking into 
account that the symptoms of sarcoidosis may resemble, or even mask, the symptoms of 
internal malignancy, physician awareness is considered crucial. Conversely, when a patient 
presents with a granulomatosis occuring at the end of a malignant hemopathy's treatment, 
this granulomatosis must be suspected to be linked to an infectious complication 
(opportunist infection, tuberculosis or other mycobacterias, pneumocystosis, fungal 
infections). The HHV-8 virus has been incriminated in the genesis of lymphoid pathologies 
and for some authors of the sarcoidosis, but this remains very controversial. The 
granulomatous pathology occuring in patients affected by a hodgkin's lymphoma motivated 
a plentiful literature(Sacks et al., 1978). Approximately 10 % of the patients presenting with 
a diagnosis of Hodgkin's lymphoma would develop granulomas affecting mainly the spleen 
and the liver. Some granulomatous vasculitis involving central nervous system have also 
been reported. Some more unusual sites have also been reported: lymph nodes, bone 
marrow, testicles, lungs. The granulomatous disease occurs generally concomitantly to the 
Hodgkin's lymphoma. Nevertheless it also can precede or arise conversely numerous years 
later. Patients with a history of sarcoidosis develop more often a Hodgkin's lymphoma than 
the general population with a relative risk of 14,1 (CI 95 %: 5,4-36,8)(Landgren et al., 2006). 
The antineoplastic treatments (chemotherapy and/or radiotherapy) are sometimes 
suspected to be causative when the granulomatosis arises with a long delay after the 
diagnosis of Hodgkin’s lymphoma. The organ areas affected by the granulomatous reaction 
can also contain a neoplastic infiltration which is generally very difficult to determine. 
Hodgkin’s patients presenting with a granulomatous disease have usually a favourable 
course. Granulomatous disease seems to be a favorable prognosis factor in term of survival 
and  relapse(O'Connell, et al., 1975; Sacks, et al., 1978). 
4. Melanomas and other skin cancers 
In the swedish study of Askling et al., the relative risk was increased for melanomas (RR: 
1,6; CI 95 %: 1-2,3) and other skin cancers (RR: 2,8; CI 95 %: 2-3,8)(Askling, et al., 1999). In a 
recent work, Sève et al examined the relation between sarcoidosis and melanoma. They 
identified 7 cases in their population of 1,199 melanoma inpatients(Seve et al., 2009). 
Including these cases, 20 cases of sarcoidosis have been described in melanoma patients in 
the literature. Fifteen patients had their sarcoidosis diagnosed after melanoma. In 7 cases, 
sarcoidosis was related to immunotherapy. Sarcoidosis presented mainly as pulmonary 
disease without severe organ involvement, with a benign evolution. In this referral center 
study showed a prevalence of sarcoidosis of 0.58% among melanoma inpatients. By 
excluding two cases related to immunotherapy, the prevalence was 0.42%, what is close to 
the prevalence of sarcoidosis found in the general population. This study does not support a 
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strong relationship between malignant melanoma and sarcoidosis. However, clinicians 
should be aware of the possibility that sarcoidosis may initially manifest or be reactivated in 
melanoma patients, especially during or after treatment with immunotherapy. Because 
sarcoidosis is a diagnostic pitfall, biopsies must always be performed before starting an 
antineoplastic treatment. Although Asking et al. found an increased incidence of other skin 
cancers presenting with sarcoidosis, very few cases are reported in the literature about this 
concern(McLoone et al., 2005; Setoyama et al., 1998). 
5. Hepatocarcinomas 
Sarcoidosis-associated hepatocellular carcinoma (HCC) is rare with only few cases 
reports(Askling, et al., 1999; Chalasani et al., 2005; Ogata et al., ; Wong et al., 1999). Such a 
rare association of sarcoidosis with HCC may reflect the presence of relatively weak 
inflammation or weak hepatocytic regeneration in sarcoid liver disease(Ogata, et al.). 
Despite a favorable-looking suggesting host immunity against the tumor, its significance on 
prognosis is unclear. 
6. Renal cancers 
Only a few publications that mention the presence of granulomatous reaction in renal cell 
cancer have been published until yet(Bottone et al., 1993; Campbell and Douglas-Jones, 1993; 
Kovacs et al., 2004; Lucci et al., 2002; Marinides et al., 1994; Moder et al., 1990). In some cases 
the granulomatous reaction is not related to the cancer but it is a primary process of the 
kidney, like xanthogranulomatous pyelonephritis, and we must note that cancer and true 
sarcoidosis may coexist(Kovacs, et al., 2004). According to the few publications that mention 
cancer associated sarcoid-like reaction, such lesions do not influence the prognosis. 
Interferon and interleukin 2 have been usual therapies for the kidney cancers during years. 
As sarcoidosis induced by interferon or high dose interleukin 2 therapies have been 
reported in the literature,  the role of this agents must be kept in mind(Logan and 
Bensadoun, 2005; Massaguer et al., 2004; Pietropaoli et al., 1999). 
7. Germ cell tumors 
I the relevant literature, several case reports and small case series have described a total of 
67 patients with “sarcoidosis” or “sarcoidosis-like reaction” and testicular germ-cell tumors 
(GCT) so far (Dick et al., ; Paparel et al., 2007). The phenomenon is clinically relevant, 
because the finding of granulomatous lesions in patients with cancer may lead to difficulties 
of interpretation resulting in appropriate treatment of both the granulomatous disease and 
the malignancy. Some data in the literature have raised the question of an increased 
incidence of sarcoidosis in GCT. It is suggested that the incidence of sarcoidosis could be 
increased following testicular cancer with an estimated incidence of 1.1% (Pandha et al., 
1995; Rayson et al., 1998). Analysis of data from 1 center suggested that the incidence of 
testicular cancer in patients with sarcoidosis was 100 times the expected rate(Rayson, et al., 
1998). Sarcoidosis is associated with different types of testicular cancer, with seminoma 
being the most common. In 80% of the cases with concomitant sarcoidosis, the sarcoidosis 
regresses simultaneously. The coexistence of sarcoidosis and testicular cancer doesn’t 
change the overall prognosis(Paparel, et al., 2007). Epidemiological studies of sarcoidosis 
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and malignancy have potential confounding factors; both maximal incidences of testicular 
cancer and sarcoidosis occur at the same age. It is known that sarcoidosis is often a latent 
disease and is more easily discovered when the clinical survey is tight as in patients treated 
and followed for cancer. Thus, a great attention has to be paid to the group used to compare 
the incidence of sarcoidosis. The coexistence of sarcoidosis and testicular cancer presents 
potential pitfalls for oncologists during initial staging and follow-up of patients. Clinicians 
who deal with testis cancer should always consider one of the “great imitator” 
granulomatosis in the differential diagnosis of patients with GCT. An usual distribution of 
metastatic spread or coincident findings such as the rash of erythema nodosum demands 
further investigation. Conventional cross-sectional imaging and functional imaging with 
FDG PET can be unreliable, and histological assessment remains the only reliable way of 
confirming the diagnosis(Dick, et al.). 
8. Lung cancers 
Several cases of the occurence of sarcoidosis and lung cancer have been reported (Kobayashi 
et al., ; Yamasawa et al., 2000). In most of these cases, sarcoidosis was present for some years 
preceding the development of lung cancer, but in some cases both diseases were detected 
simultaneously. It is sometimes difficult to determine whether non-caseinting epithelioid 
cell granulomas coexisting with lung cancer represent sarcoid reaction or true systemic 
sarcoidosis. Epidemiologically, the causal relationship between the two diseases is 
controversial. Some reports supported the theory of an association between the 2 
diseases(Brincker and Wilbek, 1974; Yamaguchi et al., 1991) but some reports did 
not(Romer, 1982; Seersholm, et al., 1997). Either causality or coincidence, lung cancer, a 
condition that can be observed in patients with sarcoidosis, should be considered in the 
differential diagnosis when suspicious findings of it are discovered(Kobayashi, et al.). 
Tumor-related sarcoid reactions may be found in lymph nodes draining an area containing 
malignant tumor, in the tumor itself, or even in non regional tissues(Segawa et al., 1996). 
The association of sarcoidal reaction and cancer makes the cancer patient with 
lymphadenopathy a diagnostic dilemma: malignant involvement of the lymph nodes is 
common, but benign diagnoses are possible and must be considered(Hunt et al., 2009). 
Sarcoidal reactions in the setting of lung cancer (NSCLC) have been identified in two 
Japenese studies of lung cancer, with an incidence rates of 1,2% and 1,3% (Kamiyoshihara et 
al., 1998; Tomimaru et al., 2007). Steinford et al found in a recent Australian work an overall 
incidence of sarcoidal reactions occuring in regional lymph nodes of NSCLC patients of 
4,3%(Steinfort and Irving, 2009). The findings were confined to patients with Stage I disease, 
with in an incidence in this group of 7,7%.  In 1975, Laurberg reported an incidence of 3,2% 
among 734 Danish patients with lung malignancy, noting that sarcoidal reactions were seen 
only in patients with Stage I disease(Laurberg, 1975). Other authors have also noted a 
significantly increased incidence in Stage I disease, though very rare occurrence in Stages II 
and III disease has been reported(Kamiyoshihara, et al., 1998; Tomimaru, et al., 2007). Most 
of the authors have noted no association with histological sub-type. Laureberg noted a 
preponderance of squamous cell tumours and postulated that the slower growth and higher 
tendency to necrosis of this tumour type may result in a more vigorous and longer-lasting 
stimulation of the regional lymph nodes(Laurberg, 1975). A significant proportion of the 
sarcoidal reactions in regional lymph nodes of lung cancers are radiologically and 
metabolically occult. It appears that metastatic involvement by NSCLC is not seen in lymph 
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nodes exhibiting sarcoidal granulomatous reactions. The sarcoidal reaction do not influence 
the prognosis, and may be a local reaction or resistance to cancer cells(Kamiyoshihara, et al., 
1998). Sarcoidosis must be considered in the differential diagnosis of patients with a history 
of malignancy who develop lymphadenopathy. It is imperative to obtain a tissue diagnosis 
before instituting therapy for presumed cancer recurrence(Hunt, et al., 2009). 
9. Breast cancers 
Lower et al reviewed the medical records of 629 women with sarcoidosis followed in the 
Interstitial Lung Disease Clinic at the University of Cincinnati for findings associated with 
breast disease(Lower et al., 2001). In addition, three women with breast cancer who had 
granulomas in proximity to their tumors were also examined. Abnormal breast 
examinations or mammograms were reported in 15 patients with sarcoidosis (2% of women 
with sarcoidosis). Breast biopsy revealed granulomas consistent with sarcoidosis in six. One 
of them developed breast cancer five years later. Breast cancer was identified in twelve 
further patients, therefore a total of thirteen patients with breast cancer were identified. Ten 
were diagnosed with breast cancer plus sarcoidosis: sarcoidosis preceded breast cancer in 
three, followed breast cancer in five, the two diseases appeared simultaneously in two. 
Three additional women with breast cancer were also evaluated and classified as patients 
with sarcoid-like reaction. Review of the mammographic and physical findings could not 
distinguish between sarcoidosis in the breast and breast cancer. The autors concluded that 
sarcoidosis patients develop breast cancer at the expected frequency. The breast cancer 
diagnosis may precede or follow that of sarcoidosis. There is no relationship between stage 
of sarcoidosis or treatment and the development of cancer. Because physical examination 
and mammography findings are unable to distinguish between sarcoidosis and malignancy, 
biopsy of all suspicious lesions in sarcoidosis is recommended. 
10. Digestif tract cancers 
The incidence of a sarcoid reaction in surgical specimens, derived from 319 Japenese gastric 
cancer patients, was first reported to be 5% (Takeuchi et al., 1982). To clarify the occurence 
of sarcoid-like reaction in the spleen of the gastric carcinoma patients, 100 consecutive 
specimens from gastrosplenectomy were examined(Kojima et al., 1997). Sarcoid-like reaction 
was observed in the lymph nodes of 13 cases (13%) and the spleen of five cases (5%). None 
of them showed any symptoms or signs indicative of systemic sarcoidosis. It seems that the 
cases with sarcoid-like reaction in the spleen ocurred more frequently in an advanced stage 
of the gastric cancer than those without this phenomenon. Epithelioid cell granulomas 
(EPGs) appeared to arise in the periarteriolar lymphoid sheaths of the spleen histologically, 
but were never found in red pulp or germinal centers. None of the 13 cases contained EPGs 
in the primary tumor. This study indicates that sarcoid-like reaction in the spleen is possibly 
not a rare phenomenon in the gastric cancer and more frequently seen in the advanced stage 
of the gastric cancer. Sarcoid-like reactions of the regional lymph nodes are more frequently 
seen in the patients with EPGs in the spleen than in those without. The incidence of sarcoid-
like reactions in the spleen seems to be closely related to those in pancreaticosplenic nodes 
and/or nodes of the hilus of the spleen. Granulomatous gastritis is a rarely observed 
pathological diagnosis. This condition often mimics gastric adenocarcinoma clinically, 
resulting in gastric resection. However, granulomatous gastritis has long been viewed as a 
benign process not observed in association with adenocarcinoma of the stomach. Newton et 
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al. described a patient with granulomatous gastritis occurring in close proximity to an area 
of superficially invading gastric adenocarcinoma. The findings in this patient did not 
support a diagnosis of Crohn's disease, tuberculosis, sarcoidosis, syphilis, histoplasmosis, 
berylliosis, or foreign-body reaction. This  unique case suggests a possible association 
between isolated granulomatous gastritis and metaplastic mucosal changes(Newton et al., 
1998). Sarcoid reactions in colorectal is considered to be quite rare. There has been some case 
reports in the Japenese literature on colorectal cancers with sarcoid reactions in the dissected 
lymph nodes or continous to the tumor(Nozoe et al., 1999). In these cases, the most 
outstanding common clinicopathologic feature was the lack of metastatic carcinoma in the 
dissected lymph nodes despite the large size of the tumors.  
11. Possible role of antineoplastic treatments in the pathogenesis of 
granulomatosis 
Immunotherapy such as interferon (IFN) and interleukine-2 (IL-2) has been reported to 
induce systemic sarcoidosis probably by reproducing some physiological mechanisms 
involved in sarcoidosis(Logan and Bensadoun, 2005; Massaguer, et al., 2004; Pietropaoli, et 
al., 1999; Raanani and Ben-Bassat, 2002). Although no specific etiology has been implicated 
in the pathogenesis of the sarcoidosis, inflammatory mediators such as IL-2 and IFN are 
probably involved(Raanani and Ben-Bassat, 2002). IFN is released spontaneously from lung 
T lymphocytes and alveolar macrophages of patients with sarcoidosis. Moreover, quiescent 
macrophages of these patients are activated by exposure to IFN. Therefore, IFN given in 
pharmacological doses could cause macrophage activation especially in patients with a 
certain predisposition and thus might induce the clinical development of sarcoidosis. IFN 
γ appears to play a major role as a mediator responsible for macrophage activation. IFN g is 
released from lung T-lymphocytes and alveolar macrophages when these cells are obtained 
from normal subjects ans are exogenously stimulated(Robinson et al., 1985). It has been 
demonstrated that the same cells from patients with sarcoidosis release this cytokine 
spontaneously. Quiescent macrophages from patients with inactive sarcoidosis are activated 
by exposure to IFN γ. There is little published evidence implicating any of the other IFNs in 
the pathogenesis of sarcoidosis. IL-2, a T helper 1 (Th1) also plays an important role in the 
pathogenesis of the granulomatous inflammation in sarcoidosis(Logan and Bensadoun, 
2005; Ziegenhagen and Muller-Quernheim, 2003). It has been postulated that a Th1 
predominant pattern may be more important in promoting granulomatous inflammation 
while a Th2 predominant pattern may be more involved in the development of fibrosis. 
There is usually a chronological link between the occurrence of the granulomatosis and the 
beginning of the immunotherapy. The association can so rapidly be suspected. The 
occurrence of granulomatosis attributed to the classic antineoplastic chemotherapies is 
exceptionally reported in the literature. 
To date, alpha  interferon appears to be the most common agent that causes sarcoidosis in 
patients treated for malignancies, although many other agents such as cisplatin have also 
been reported(Shigemitsu, 2008). 
12. Diagnostic strategy 
Clinicians in charged with tumoral pathology would be interested in a non-invasive test 
allowing him to avoid a systematic a biopsy to distinguish cancer and benign pathology. 
Nevertheless clinicians have to keep in mind that neoplastic tissue and sarcoidosis can coexist.  
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Differenciation between malignant and benign pulmonary nodules is a common probleme 
encountered by radiologists which has provided the impetus to explore alternative imaging 
techniques(Chang et al., 2006). Accurates diagnosis can reduce unnecessary thoracotomies 
in patients with benign diseases. Metabolic imaging with 2-(18F)-fluoro-2-deoxy-D-glucose 
positron emission tomography (PET) is being used more and more to differentiate benign 
from malignant focal lesions and it has been shown to be more efficious than conventional 
chest CT. Howewer, fluorodeoxyglucose (FDG) is not a cancer-specific agent, and false 
positive findings in benign diseases have been reported in active inflammation or infection, 
causing false-positive results. Active granulomatous conditions with agregation of 
inflammatory cells in sarcoidosis results in accumulation of FDG and it has been suggested 
that the intensity of FDG uptake may reflect disease activity(Brudin et al., 1994). A 
retrospective study was conducted by Chowdhury et al. to evaluate the prevalence of 
sarcoid-like reaction to malignancy detected using integrated 18 FDG PET/CT in patients 
undergoing staging or restaging of solid-organ malignancy(Chowdhury et al., 2009). 
Sarcoid-like reaction was initially suspected in 23 of the 2048 (1.1%) FDG PET/CT 
examinations, with the diagnosis confirmed histologically or by clinico-radiological follow-
up in 13 of the 23 cases (57%). Sarcoid-like reaction was more commonly seen in patients 
undergoing FDG PET/CT for restaging of suspected recurrence rather than for primary 
tumour staging (77% versus 23%; p=0.05). The mean maximum standardized uptake value 
(SUV(max)) of confirmed hilar and mediastinal sarcoid-like reaction was 7.3 (range 3.1-13.6). 
Symmetric hilar uptake was demonstrated in 11 of the 13 (85%) and all 13 had additional 
mediastinal nodal uptake. Pulmonary uptake was seen in seven of the 13 cases (54%). Extra-
thoracic involvement was present in eight of the 13 (61.5%), including nodal, splenic, and 
hepatic lesions. Sarcoid-like reaction was suspected in 1.1% of cancer patients at FDG 
PET/CT examination, with confirmation of the diagnosis in 0.6%. With the increasing use of 
FDG PET/CT in cancer patients, it is important to be aware of the prevalence of this 
uncommon, but important, disease entity and to consider this diagnosis in appropriate cases 
in order to avoid a false-positive interpretation of metastatic disease. Some authors have 
suggested that early metabolic response to systemic corticosteroid treatment may be used as 
a tool in the establishment of final diagnosis when sarcoidosis is suspected in a cancer 
patient and could be capable of differentiating cancer from sarcoidosis in the case of 
coexisting diseases(Aide et al., 2009). New radiopharmaceutical probes are under 
development and will improve the performance of PET(Bonardel et al., 2011). 
Hence clinicians must be aware that a florid sarcoid-like reaction can camouflage tumor 
recurance and hence, should preferably perform multiple sections of the tissues or perform 
multiple biopsies at different sites in addition to continually following these patients for 
tumor recurrence(Trikudanathan, et al.). This is particularly true for Hodgkin's lymphomas 
and non-Hodgkin's lymphomas. So when a patient presents with an atypical sarcoidosis 
(age of beginning > 50 years, change of the general health status, no involvement of the lung 
or of the mediastinum, personal history of cancer), physicians must take the diagnosis of 
sarcoidosis very cautiously. The pathologist will have to look the whole block of inclusion 
with a particular attention. He also will have to look for cytokeratin expressions and to 
search a clonality. In this context, a corticotherapy must be avoided not to erase later the 
possibility of bringing to light lymphoma's cells. 
13. Conclusion 
Thanks to recent epidemiological studies the links between sarcoidoses and cancer are 
finally demonstrated. Nevertheless the over-risk of cancer after sarcoidosis remains modest. 
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The clinician has to remain particularly watchful when he is in front of an atypical 
sarcoidosis. In this situation he has first to suspect a possible lymphoma or an infectious 
pathology. This approach can avoid to delay an adapted specific treatment. 
 
 
 
- Infections:  
• Fungal: Histoplasma, Coccidioides, Blastomyces, Sporotrichum, Pneumocystis 
jirovecii, Cryptococcosis 
• Mycobacterial: Mycobacterium tuberculosis, Atypical mycobacterial infections 
(Mycobacterium avium complex, Mycobacterium gordonae, Mycobacterium kansasii) 
• Bacterial : Brucella, Chlamydia, Tularemia 
• Spirochaeta : Treponema (Pallidum, Pertenue carateum) 
• Parasites: Leshmaniasis, Toxoplasmosis 
• Virus (Cytomegalovirus, Immune Reconstitution Inflammatory Syndrome 
during HIV) 
 
- Occupational and environmental exposures: 
• Hypersensitivity pneumonitis: Farmer’s lung, Bird fancier’s, Other (> 50 types) 
• Chemical/drugs: Silica, Calcium carbonate or oxalate, Metals (Chronic 
beryllium disease, titanium, zirconium, aluminium), Glass fibers, Hydrocarbons, 
Methotrexate, BCG therapy, Interferon…) 
 
- Immunologic:  
• Sarcoidosis, Wegener granulomatosis, Crohn disease, Rheumatoid arthritis 
 
- Immunodeficiency : 
• Common Variable Immune Deficiency… 
 
- Malignancy: 
• Radiation and chemotherapy 
• Neoplasia (carcinoma, seminoma, sarcoma, lymphoma) 
• Sarcoid-like reaction 
 
 
Table 1. Main diseases (affecting preferentially the lungs) associated with granulomas on 
histologic examination 
 
 
 
- Granulomatous reaction in loco-regional adenopathy 
- Unfortuitous association between cancer and sarcoidosis but without paraneoplastic 
characteristics 
- Opportunist infection  
- Antineoplastic therapy 
 
 
Table 2. Main contexts of granulomatosis during cancers 
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Features Local sarcoid reaction Multisystem sarcoidosis 
Organ(s) involved Single Multiorgan 
Age Any Middle age 
Associated disease  Malignancy None 
Pathogenesis 
May be local immune 
response 
Unknown 
Chest radiograph Normal Abnormal 
Delayed hypersensitivity Normal Usually depressed 
Elevated serum ACE  Rare Common 
Kveim-Siltzbach test Negative Positive 
BAL lymphocytosis Absent Present 
Slit lamp examination Normal Abnormal in 15-20% 
Hypercalcemia Absent Common 
Gallium body scan Localized uptake Multisystem uptake 
ACE, angiotensin-converting enzyme ; BAL, bronchoalveolar lavage. Reproduced from Shigemitsu, 
2008.  
Table 3. Difference between a local sarcoid reaction and systemic sarcoidosis 
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